The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Please provide your email address to receive an email when new articles are posted on . The RHEIA trial included enrolled-only women randomly assigned to transcatheter vs. surgical aortic valve ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement was noninferior to surgery for death and stroke at 1 year in a real-world ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Transcatheter aortic valve replacement (TAVR) is a procedure that can treat narrowing of the aortic valve in the heart. It involves an expandable replacement valve that helps improve blood flow. A ...

High-risk surgical patients with severe aortic stenosis who underwent a transcatheter aortic valve replacement experienced higher one-year survival rates than patients who underwent traditional ...

Bethesda Heart, part of Bethesda Heart Hospital East in Boynton Beach, Fla., has performed its 100th transcatheter aortic valve replacement in under two years since launching the TAVR program in March ...

Saint Alphonsus in Boise earned a three-star TAVR ranking from STS and ACC, placing it among the nation’s top heart programs ...